Abstract：
Small intestinal Neuroendocrine Neoplasms (SI-NENs) are the most common primary malignancy of the small bowel. The aim of this study is to define the survival of patients with an SI-NEN in Auckland, Aotearoa New Zealand (AoNZ).
A retrospective study of all patients diagnosed with a jejunal or ileal SI-NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data.
One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10-year disease-specific survival for all patients was 66.1% (95% CI 56.5-75.7%) and 61.8% (95% CI 51.8-71.8%), respectively. Ten-year disease-specific survival was 100% for stage I and II, 74% (95%CI 61.7-84.4%) for stage III and 33.9% (95%CI 16.9-35.6%) for stage IV SI-NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92-5.5) nor distant resection (HR 1.72, 95% CI 0.63-4.7) were significantly associated with a disease-specific or overall survival benefit.
This study demonstrates that stage at SI-NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection.
A retrospective study of all patients diagnosed with a jejunal or ileal SI-NEN in the Auckland region between 2000 and 2012 was performed. The New Zealand NETwork! Registry was searched to identify the study cohort. Retrospective data collection was performed to collect stage, survival and follow up data.
One hundred and seven patients were included in the study. The mean age of patients was 62.8 years (SD 11.9). The 5 and 10-year disease-specific survival for all patients was 66.1% (95% CI 56.5-75.7%) and 61.8% (95% CI 51.8-71.8%), respectively. Ten-year disease-specific survival was 100% for stage I and II, 74% (95%CI 61.7-84.4%) for stage III and 33.9% (95%CI 16.9-35.6%) for stage IV SI-NEN. Eleven of 40 (27.5%) patients with stage III disease had recurrence and 3 of 7 (42.8%) patients with stage IV disease had recurrence. In patients with stage IV disease, neither primary resection (HR 2.25, 95% CI 0.92-5.5) nor distant resection (HR 1.72, 95% CI 0.63-4.7) were significantly associated with a disease-specific or overall survival benefit.
This study demonstrates that stage at SI-NEN diagnosis is associated with survival, but resection of the primary or distant metastases in patients with stage IV disease is not. There was no recurrence in patients with stage I or II disease after complete resection.
摘要：
小肠神经内分泌肿瘤(SI-NENs)是小肠最常见的原发性恶性肿瘤。这项研究的目的是确定奥克兰患有SI-NEN的患者的生存率，Aotearoa新西兰(AoNZ)。
对2000年至2012年在奥克兰地区诊断为空肠或回肠SI-NEN的所有患者进行了回顾性研究。搜索了新西兰网络登记处以确定研究队列。进行回顾性数据收集以收集阶段，生存和随访数据。
研究中纳入了一百零七名患者。患者的平均年龄为62.8岁（SD11.9）。所有患者的5年和10年疾病特异性生存率分别为66.1%（95%CI56.5-75.7%）和61.8%（95%CI51.8-71.8%），分别。I期和II期的10年疾病特异性生存率为100％，第三阶段为74%（95CI61.7-84.4%），第四阶段SI-NEN为33.9%（95CI16.9-35.6%）。40例III期疾病患者中有11例（27.5％）复发，7例IV期疾病患者中有3例（42.8％）复发。在IV期疾病患者中，初次切除(HR2.25,95%CI0.92~5.5)和远处切除(HR1.72,95%CI0.63~4.7)均未与疾病特异性或总体生存获益显著相关.
这项研究表明，SI-NEN诊断阶段与生存有关，但IV期患者的原发或远处转移不切除。I期或II期患者完全切除后无复发。
对2000年至2012年在奥克兰地区诊断为空肠或回肠SI-NEN的所有患者进行了回顾性研究。搜索了新西兰网络登记处以确定研究队列。进行回顾性数据收集以收集阶段，生存和随访数据。
研究中纳入了一百零七名患者。患者的平均年龄为62.8岁（SD11.9）。所有患者的5年和10年疾病特异性生存率分别为66.1%（95%CI56.5-75.7%）和61.8%（95%CI51.8-71.8%），分别。I期和II期的10年疾病特异性生存率为100％，第三阶段为74%（95CI61.7-84.4%），第四阶段SI-NEN为33.9%（95CI16.9-35.6%）。40例III期疾病患者中有11例（27.5％）复发，7例IV期疾病患者中有3例（42.8％）复发。在IV期疾病患者中，初次切除(HR2.25,95%CI0.92~5.5)和远处切除(HR1.72,95%CI0.63~4.7)均未与疾病特异性或总体生存获益显著相关.
这项研究表明，SI-NEN诊断阶段与生存有关，但IV期患者的原发或远处转移不切除。I期或II期患者完全切除后无复发。
